Navigation Links
Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors
Date:6/11/2008

DANBURY, Conn., June 11 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Barry Ginsberg, M.D., Ph.D., has been elected as a new member of its Board of Directors, effective June 10, 2008. Dr. Ginsberg is currently Chief Executive Officer of Diabetes Technology Consultants where he advises Fortune 500 companies in the field of diabetes.

"We are pleased to welcome Barry to our Board of Directors at such an important time for Biodel," stated Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Barry's diabetes expertise and experience as a seasoned advisor to commercial stage companies will provide invaluable insights and contributions to Biodel as we prepare to file VIAject(TM)'s New Drug Application by the end of 2008."

Dr. Ginsberg joins the Company's Board of Directors with over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and Therafuse, and is a Scientific Advisory Board Member at Covidien, Metacure, Glucolight and Becton Dickinson Diabetes HealthCare. While a Professor of Medicine at the University of Iowa (1977-90), he was a Principal Investigator of the prestigious Diabetes Control and Complications Trial.

Biodel also announced that Albert Cha, M.D., Ph.D. will depart from the Company's Board of Directors. Dr. Cha, a Managing Partner of Vivo Ventures, joined the Company's Board of Directors in July 2006.

"Albert has been a valued source of counsel and he served our Company and its shareholders well during our transition from an early stage private company to a public company with a late stage Phase III product candidate. We thank him for his service and wish him well," stated Dr. Steiner.

About Biodel Inc.

'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
4. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
5. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
8. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
9. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
10. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
11. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2Tropical birds waited for land crossing between North and South America: UBC study 2U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 1U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 2U S Debut 3A Holistic Health And Beauty From The Rainforest New Book Reveals Closely Guarded Malaysian Health and Beauty Secrets Introducing the Wo 51638 3CardioNet Terminates Merger With Biotel 51633 1Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 1Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 2Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 3Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 4Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 5Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 6Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 7Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 8Santaris Pharma Interim Report for the Period 1 January to 30 June 2009 13023 9